Log In
BCIQ
Print this Print this
 

ATIR201

  Manage Alerts
Collapse Summary General Information
Company Kiadis Pharma N.V.
DescriptionCell-based therapy containing mismatched donor lymphocytes depleted of alloreactive T cells
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentPreclinical
Standard IndicationThalassemia
Indication DetailsTreat thalassemia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today